Izonsteride
From Wikipedia, the free encyclopedia
| Clinical data | |
|---|---|
| Other names | LY-320,236 |
| Routes of administration | By mouth |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C24H26N2OS2 |
| Molar mass | 422.61 g·mol−1 |
| 3D model (JSmol) | |
| |
Izonsteride (developmental code name LY-320,236) is a selective inhibitor of the 5α-reductase, with dual effects on both the type I and type II isoforms of the enzyme.[1] It was under development by Eli Lilly and Company and Fujisawa for the treatment of benign prostatic hyperplasia but was never marketed.[2][3] Izonsteride may also be useful in the treatment of androgenic alopecia.[1]
